Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Try This Tonight Set 2 alarms on your phone right now: 12:00pm: "Last caffeine." 3 hours before your usual bedtime: "Last food." Put your phone charger in the bathroom or hallway
A simple prostate-specific antigen blood test, a blood pressure check or lab work to monitor cholesterol and glucose can give us the early warning signs we need to keep you healthy and active
Any references to biological activity, molecular pathways, or scientific research are provided solely for educational and informational purposes within the context of laboratory and preclinical research
Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks Roche reported positive topline results from its Phase II clinical trial, CT388-103, evaluating CT-388, Roches investigational dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist being developed for the treatment of obesity
Be mindful of the following: Share your complete medical history, especially if you have: Notify your provider if you are pregnant, planning to become pregnant, or breastfeeding: Providing inaccurate health information to obtain treatment may result in harm, including death
During surgery, attention should be given to radical resection and lymph node dissection, and to the identification and protection of adjacent tissues and organs, such as the recurrent laryngeal nerve and the parathyroid glands
US$ 29.32
US$ 29.53
US$ 24.34
US$ 23.08
US$ 28.98
US$ 24.02
US$ 27.11
